[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Barzon L, Masi G, Fincati K, Pacenti M, Pezzi V, Altavilla G, Fallo F, Palù G: Shift from Conn's syndrome to Cushing's syndrome in a recurrent adrenocortical carcinoma. Eur J Endocrinol; 2005 Nov;153(5):629-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shift from Conn's syndrome to Cushing's syndrome in a recurrent adrenocortical carcinoma.
  • OBJECTIVE: Adrenocortical tumors may originate from the zona glomerulosa, zona fasciculata, or zona reticularis and be associated with syndromes due to overproduction of mineralocorticoids, glucocorticoids, or androgens respectively.
  • We report an unusual case of recurrent adrenocortical carcinoma (ACC), which seems to contradict the paradigm of functional adrenal zonation.
  • CASE REPORT: A male patient presented with severe primary aldosteronism due to an ACC, which relapsed after adrenalectomy and adjuvant mitotane therapy.
  • After removal of the tumor recurrence and eight cycles of chemotherapy with etoposide, doxorubicin and cisplatin, the patient presented again with ACC masses, but in association with overt Cushing's syndrome and normal aldosterone levels.
  • METHODS AND RESULTS: Extensive pathologic examination showed that this shift in steroid hormone production was paralleled by an attenuation of tumor cell atypia and polymorphism, whereas gene expression profile analysis demonstrated a change in expression of adrenal steroidogenic enzymes.
  • Moreover, cancer progression was associated with overexpression of the inhibin-alpha subunit, which could have contributed to the phenotypic changes.
  • CONCLUSIONS: This case of recurrent ACC demonstrates that adrenocortical cells can reverse their differentiation program during neoplastic progression and change their specific hormone synthesis, as a consequence of modifications in the expression profile of steroidogenic enzymes and cofactors.
  • We hypothesize that this shift in steroid hormone secretion is a consequence of chromosome amplification induced by chemotherapy.
  • These findings, besides opening new perspectives to study adrenocortical cell plasticity and potential, demonstrate how conventional clinical and pathologic evaluation can be combined with genomic analysis in order to dissect thoroughly the biology of cancer.


2. Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF: Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology; 2009 Apr 7;72(14):1217-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.
  • OBJECTIVE: Bevacizumab has been shown to be effective in the treatment of recurrent glioblastoma in combination with chemotherapy compared with historic controls but not in randomized trials.
  • METHODS: We conducted a retrospective analysis of patients treated for recurrent glioblastoma with bevacizumab vs a control group of patients, comparing progression-free survival (PFS) and overall survival (OS) between the two groups, and performed subgroup analysis based on age and performance status.
  • CONCLUSIONS: Bevacizumab in combination with chemotherapy may be a more effective treatment for recurrent glioblastoma and warrants further randomized prospective studies to determine its effect on survival.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy
  • [MeSH-minor] Adrenal Cortex Hormones / adverse effects. Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Aged, 80 and over. Aging / metabolism. Anti-Inflammatory Agents / adverse effects. Anti-Inflammatory Agents / therapeutic use. Antibodies, Monoclonal, Humanized. Bevacizumab. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Oligonucleotide Array Sequence Analysis. Quality of Life. Retrospective Studies. Survival. Vascular Endothelial Growth Factor A / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1399-405 [12684411.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Neurology. 1994 Apr;44(4):675-80 [8164824.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4051-8 [15899794.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Dec;20(6):1337-61 [17113467.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2592-8 [17473188.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2601-6 [17577040.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Genome Biol. 2007;8(6):R112 [17570842.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] Eur J Cancer. 2000 Mar;36(4):447-51; discussion 451-2 [10717519.001]
  • (PMID = 19349600.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ PMC2677488
  •  go-up   go-down


3. Markel G, Imazio M, Brucato A, Adler Y: Colchicine for the prevention of recurrent pericarditis. Isr Med Assoc J; 2008 Jan;10(1):69-72
Hazardous Substances Data Bank. COLCHICINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colchicine for the prevention of recurrent pericarditis.
  • The most troublesome complication of acute pericarditis is recurrent episodes of pericardial inflammation, which occur in 15-32% of cases.
  • The optimal method for prevention has not been fully established; accepted modalities include non-steroidal anti-inflammatory drugs, corticosteroids, immunosuppressive agents, and pericardiectomy.
  • Based on the proven efficacy of colchicine in familial Mediterranean fever, several small and large-scale international clinical trials have shown the beneficial effect of colchicine therapy in preventing recurrent pericarditis.
  • It was also found that pretreatment with corticosteroids substantially attenuates the efficacy of colchicine, as evidenced by significantly more recurrence episodes and longer therapy periods.
  • Colchicine is a safe and effective modality for the treatment and prevention of recurrent pericarditis, especially as an adjunct to other modalities, since it provides a sustained benefit superior to all current modalities.
  • The safety profile seems superior to other drugs such as corticosteroids and immunosuppressive drugs.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Colchicine / therapeutic use. Pericarditis / drug therapy
  • [MeSH-minor] Acute Disease. Adrenal Cortex Hormones / therapeutic use. Humans. Secondary Prevention

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300579.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Inflammatory Agents; SML2Y3J35T / Colchicine
  • [Number-of-references] 21
  •  go-up   go-down


Advertisement
4. Borrelli D, Bergamini C, Borrelli A, Reddavide S, Lassig R, Valeri A: [Surgical strategy in the treatment of adrenal cortex cancer. Expanded and repeated interventions]. Ann Ital Chir; 2003 May-Jun;74(3):311-7
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical strategy in the treatment of adrenal cortex cancer. Expanded and repeated interventions].
  • [Transliterated title] La strategia chirurgica nel trattamento del carcinoma cortico surrenalico. Gli interventi allargati ed iterativi.
  • AIM OF THE STUDY: To analyze our patients affected by adreno-cortical carcinoma (ACC) considering in particular the therapeutical approach in case of local recurrence or metastasis, and to compare our results with those from literature.
  • Adjuvant treatment was administered in 17 patients, 4 out of which were re-operated.
  • RESULTS: Only one patient died in the perioperative period for hyperacute adrenal failure.
  • Local recurrence or metastatic disease was observed in 27 patients, out of which only 9 were eventually surgically treated, once or more times.
  • Interestingly, one patient who has been re-operated three times, is still alive and disease-free after 7 years from the first recurrence.
  • CONCLUSIONS: According with data from literature, we conclude that surgical therapy of recurring local or metastatic ACC is up to now the best treatment, independently from the original stage of the disease.
  • Controversies still remain about the utility of adjuvant chemotherapy in the primary and the recurrent disease.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenalectomy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Laparoscopy. Life Tables. Lymph Node Excision. Male. Middle Aged. Mitotane / therapeutic use. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Recurrence, Local. Palliative Care. Reoperation. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14677288.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 78E4J5IB5J / Mitotane
  • [Number-of-references] 26
  •  go-up   go-down


5. Kishi K, Fujii T, Kurosaki A, Nakata K, Yoshimura K: Recurrence of inflammatory pseudotumor of the lung after eleven years of remission. Intern Med; 2009;48(12):1079-83
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The standard treatment of inflammatory pseudotumor of the lung is surgical excision.
  • However, little data is available on steroid therapy in patients with the unresectable disease.
  • Here, we report a patient with recurrent inflammatory pseudotumor of the lung with pleural involvement who had been successfully treated with corticosteroid eleven years previously.
  • Like the previous treatment, retreatment with corticosteroid proved to be effective for the recurred lesion.
  • In addition, the patient had developed extramammary Paget's disease and bladder cancer after the initial onset of inflammatory pseudotumor.
  • Steroid therapy could be an optional modality in treating unresectable inflammatory pseudotumor, although long-term follow-up is definitely necessary.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Plasma Cell Granuloma, Pulmonary / diagnosis. Plasma Cell Granuloma, Pulmonary / drug therapy
  • [MeSH-minor] Aged. Humans. Male. Recurrence. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19525603.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


6. Gonzalez RJ, Tamm EP, Ng C, Phan AT, Vassilopoulou-Sellin R, Perrier ND, Evans DB, Lee JE: Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery; 2007 Dec;142(6):867-75; discussion 867-75
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma.
  • BACKGROUND: Adrenal cortical carcinoma (ACC) is a rare disease in which recurrence after surgery is common.
  • Mitotane is the primary systemic treatment for recurrent ACC; data are limited regarding the impact of mitotane on recurrent ACC.
  • Mitotane was given to 67 evaluable patients with recurrent ACC.
  • CONCLUSIONS: Patients with recurrent ACC who have stable or responding disease to mitotane have a more favorable prognosis than those who progress.
  • Mitotane should be considered in most patients with recurrent ACC, including as preoperative therapy for those with recurrent disease considered for surgical resection.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenal Cortex Neoplasms / surgery. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Predictive Value of Tests. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18063070.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


7. Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS: Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist; 2010;15(12):1329-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We assessed corticosteroid use in patients with recurrent glioblastoma treated with bevacizumab (BEV) in the BRAIN study (J Clin Oncol 2009;27:4733-4740).
  • METHODS: BRAIN was a phase II, multicenter, randomized, noncomparative trial of BEV alone (n = 85) or in combination with irinotecan (CPT-11) (n = 82) in adults with recurrent glioblastoma.
  • Median corticosteroid dose for patients who used corticosteroids at baseline was summarized by treatment arm; the percentage of patients who had sustained (≥50% corticosteroid dose reduction for ≥50% of time on study drug) or complete (discontinuation of corticosteroid for ≥25% of time on study drug) reduction in corticosteroid dose overall and by objective response and progression-free survival was calculated.
  • RESULTS: In each treatment group, 50% of patients were using systemic corticosteroids at baseline.
  • The majority of those experienced a reduction in dose while receiving BEV-based therapy.
  • Approximately 64% of patients who used corticosteroids while receiving BEV-based therapy experienced infection.
  • CONCLUSION: BEV may have corticosteroid-sparing effects in patients with recurrent glioblastoma.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Bevacizumab. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Drugs. 1995 Feb;6(1):19-33 [7756680.001]
  • [Cites] Biochem Pharmacol. 1999 Jul 15;58(2):363-8 [10423179.001]
  • [Cites] J Neurooncol. 2006 Dec;80(3):313-32 [16807780.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] J Neurooncol. 2009 Feb;91(3):329-36 [18953493.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • (PMID = 21147867.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ PMC3227925
  •  go-up   go-down


8. Seeber J, Reimer D, Müller-Holzner E, Spizzo G, Sepp N, Wiesbauer P, Marth C, Zeimet AG: Fallopian tube cancer associated with paraneoplastic dermatomyositis -- asymptomatic multivisceral exacerbated dermatomyositis mimicking recurrent widespread malignant disease: case report. Eur J Gynaecol Oncol; 2008;29(2):168-70
Genetic Alliance. consumer health - Fallopian Tube Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fallopian tube cancer associated with paraneoplastic dermatomyositis -- asymptomatic multivisceral exacerbated dermatomyositis mimicking recurrent widespread malignant disease: case report.
  • OBJECTIVE: To report an uncommon case of a recurrent episode of primarily paraneoplastic dermatomyositis which was completely disconnected from the initially triggering malignancy and manifested as a silent pure multivisceral exacerbation.
  • CASE: A 70-year-old woman presented with a pure multivisceral episode of dermatomyositis without characteristic musculo-cutaneous symptoms one year after successful treatment of fallopian tube carcinoma with complete resolvement of a concomittant paraneoplastic dermatomyositis.
  • The uncommon manifestation of recurrent dermatomyositis involving the lungs, spleen and liver, both adrenal glands and abdominal lymph nodes, mimicked a highly disseminated recurrence of the fallopian tube cancer.
  • Physicians participating in the interdisciplinary tumor board were misled to opt for reinductive chemotherapy.
  • Only histologic diagnosis obtained from multiple biopsies uncovered the inflammatory nature of the disease and spared the patient unneeded chemotherapy.
  • CONCLUSION: Asymptomatic multivisceral dermatomyositis may mimic metastatic spread of the initially underlying malignancy and may misdirect therapeutic strategies towards inadequate antineoplastic treatment.
  • [MeSH-major] Carcinoma / complications. Dermatomyositis / physiopathology. Fallopian Tube Neoplasms / complications. Paraneoplastic Syndromes / physiopathology
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Aged. Cryptogenic Organizing Pneumonia / etiology. Cryptogenic Organizing Pneumonia / radiography. Female. Humans. Recurrence. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Dermatomyositis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459555.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


9. Khan TS, Sundin A, Juhlin C, Wilander E, Oberg K, Eriksson B: Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer. Med Oncol; 2004;21(2):167-77
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer.
  • The efficacy and tolerability of a combination of vincristine, cisplatin, teniposide, and cyclophosphamide (OPEC) in 11 patients (median age, 45 yr) with recurrent and/or metastatic adrenocortical cancer (ACC) (seven functional and four nonfunctional) were evaluated.
  • All patients received this regimen after the failure of streptozocin and o,p'-DDD (SO) combination therapy.
  • The median duration of treatment was 6 mo.
  • The overall 2-yr survival rate was 82% and the median survival since diagnosis was 44 mo while it was 21 mo since start of OPEC therapy.
  • A total of 60 cycles of chemotherapy were given to all patients; grade 1-2 toxicity occurred in 57 cycles, while grade 3 toxicity was observed only in two cycles, according to NCI's Common Toxicity Criteria.
  • We conclude that the OPEC regimen may be considered in recurrent or metastatic ACC as a second-line medical treatment.
  • However, the combination is accompanied by considerable side effects and dose modifications are necessary in order to be able to recommend the treatment.
  • This regimen needs further evaluation compared with SO therapy preferably in a randomized multicenter trial.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Survival Analysis. Teniposide / administration & dosage. Teniposide / adverse effects. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1990 Apr 26;322(17):1195-201 [2325710.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):239-42 [11464894.001]
  • [Cites] Cancer. 1991 Jun 15;67(12):2997-3000 [2044046.001]
  • [Cites] Med Klin (Munich). 2001 Jul 15;96(7):371-7 [11494911.001]
  • [Cites] Surgery. 1992 Dec;112(6):963-70; discussion 970-1 [1455321.001]
  • [Cites] Med Pediatr Oncol. 1992;20(3):246-8 [1574038.001]
  • [Cites] CA Cancer J Clin. 1987 Nov-Dec;37(6):348-65 [3119168.001]
  • [Cites] Cancer. 2002 May 1;94(9):2333-43 [12015757.001]
  • [Cites] Cancer Treat Rep. 1980 Aug-Sep;64(8-9):909-13 [7448828.001]
  • [Cites] Med Pediatr Oncol. 1989;17(1):62-5 [2913479.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] Tumori. 1992 Oct 31;78(5):345-8 [1494808.001]
  • [Cites] Arch Surg. 1991 Apr;126(4):457-61 [1706914.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):161-5 [8418229.001]
  • [Cites] Cancer. 1987 Apr 15;59(8):1398-403 [2949824.001]
  • [Cites] Cancer. 1986 Nov 15;58(10):2198-202 [3756767.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1281-7 [11106117.001]
  • [Cites] Am J Clin Oncol. 1996 Jun;19(3):229-31 [8638530.001]
  • [Cites] JAMA. 1973 Mar 5;223(10):1109-12 [4739370.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2194-200 [9827725.001]
  • [Cites] World J Urol. 1999 Feb;17(1):26-34 [10096148.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1159-65 [10699907.001]
  • [Cites] Acta Endocrinol (Copenh). 1990 May;122(5):656-63 [2141212.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3145-55 [8242539.001]
  • [Cites] Eur J Surg Oncol. 1990 Dec;16(6):500-6 [2253796.001]
  • [Cites] World J Surg. 2001 Jul;25(7):927-33 [11572034.001]
  • [Cites] Minerva Endocrinol. 1995 Mar;20(1):105-9 [7544429.001]
  • [Cites] Arch Surg. 1982 Sep;117(9):1142-6 [7115060.001]
  • [Cites] Cancer Treat Rep. 1987 Feb;71(2):222-4 [2433038.001]
  • [Cites] Am J Med. 1966 Oct;41(4):581-92 [5923599.001]
  • (PMID = 15299189.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 957E6438QA / Teniposide; Q20Q21Q62J / Cisplatin; OPEC protocol 1
  •  go-up   go-down


10. Ryan CJ, Small EJ: Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology; 2003 Dec 29;62 Suppl 1:87-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of secondary hormonal therapy in the management of recurrent prostate cancer.
  • Androgen ablation remains the cornerstone of the systemic management of prostate cancer.
  • For the patient with progressive disease after androgen deprivation, multiple therapeutic options are available and include antiandrogen withdrawal, chemotherapy, and secondary hormonal agents.
  • In addition to the use of oral antiandrogens, active secondary hormonal therapies include adrenolytic agents such as ketoconazole and aminoglutethimide, corticosteroids and estrogenic compounds.
  • This article reviews the clinical trial data for these various agents and discusses their role in the management of patients with advanced prostate cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgens. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Neoplasms, Hormone-Dependent / drug therapy. Prostatic Neoplasms / drug therapy. Salvage Therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adrenal Glands / drug effects. Androgen Antagonists / adverse effects. Androgen Antagonists / therapeutic use. Clinical Trials as Topic / methods. Combined Modality Therapy. Disease-Free Survival. Estrogens / therapeutic use. Forecasting. Gonadotropin-Releasing Hormone / agonists. Gonadotropin-Releasing Hormone / antagonists & inhibitors. Humans. Male. Neoplasm Proteins / blood. Neoplasm Recurrence, Local / drug therapy. Orchiectomy. Prostate-Specific Antigen / blood. Prostatectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14747046.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Androgen Antagonists; 0 / Androgens; 0 / Antineoplastic Agents, Hormonal; 0 / Estrogens; 0 / Neoplasm Proteins; 33515-09-2 / Gonadotropin-Releasing Hormone; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


11. Mut M, Schiff D, Dalmau J: Paraneoplastic recurrent multifocal encephalitis presenting with epilepsia partialis continua. J Neurooncol; 2005 Mar;72(1):63-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic recurrent multifocal encephalitis presenting with epilepsia partialis continua.
  • We report a 46-year-old female patient in whom epilepsia partialis continua was the initial presentation of small cell lung cancer.
  • Intracranial lesions and neurological symptoms remitted after corticosteroids, chemotherapy, and radiotherapy.
  • Both episodes showed a distinctive response to immunosuppressive therapy.
  • The diagnostic challenges of the highly variable clinical presentations and therapeutic approaches to paraneoplastic multifocal encephalitis are discussed with relevant literature review.
  • [MeSH-major] Carcinoma, Small Cell / complications. Encephalitis / etiology. Epilepsia Partialis Continua / etiology. Lung Neoplasms / complications. Paraneoplastic Syndromes, Nervous System / etiology
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Female. Humans. Immunosuppressive Agents / therapeutic use. Magnetic Resonance Imaging. Middle Aged. Recurrence. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Encephalitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 2001 Jun;124(Pt 6):1138-48 [11353730.001]
  • [Cites] Lung Cancer. 2003 Sep;41(3):245-58 [12928116.001]
  • [Cites] Semin Oncol. 1997 Jun;24(3):318-28 [9208887.001]
  • [Cites] Ann Neurol. 1999 Feb;45(2):255-8 [9989630.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):36-44 [14708025.001]
  • [Cites] Medicine (Baltimore). 1992 Mar;71(2):59-72 [1312211.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):479-82 [10727484.001]
  • [Cites] J Neurol Sci. 2003 Sep 15;213(1-2):77-82 [12873758.001]
  • [Cites] Neurology. 2003 May 27;60(10 ):1668 [12771260.001]
  • [Cites] Radiother Oncol. 1999 Jun;51(3):197-203 [10435813.001]
  • [Cites] Brain. 2000 Jul;123 ( Pt 7):1481-94 [10869059.001]
  • [Cites] Semin Neurol. 2003 Jun;23(2):215-24 [12894387.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2866-72 [9256130.001]
  • (PMID = 15803377.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Immunosuppressive Agents
  •  go-up   go-down


12. Kuruba R, Gallagher SF: Current management of adrenal tumors. Curr Opin Oncol; 2008 Jan;20(1):34-46
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of adrenal tumors.
  • PURPOSE OF REVIEW: Adrenal tumors evoke considerable interest and diagnostic challenges.
  • This rare group of tumors includes functional tumors with a gamut of clinical presentations, as well as adrenocortical carcinoma, with its advanced disease at presentation and dismal prognosis posing additional challenge.
  • Increasing detection of incidentalomas adds further interest with the concomitant diagnostic and management dilemmas.
  • RECENT FINDINGS: Significant advances have been made in diagnostic imaging modalities for identifying malignancy risk in adrenal incidentalomas.
  • Considerable progress has occurred in understanding adrenocortical carcinoma pathogenesis from the study of genetics at the germline level in familial carcinomas, as well as at the somatic level by analyzing molecular alterations in sporadic tumors; this research supplies opportunities to develop novel therapeutic agents against a tumor with poor prognosis.
  • SUMMARY: Laparoscopic adrenalectomy has emerged as standard of care in the treatment of functional benign adenomas and nonfunctional tumors larger than 4 cm when adrenocortical carcinoma is not suspected.
  • Open adrenalectomy with en-bloc excision has been the mainstay for primary and recurrent adrenocortical carcinoma due to the lack of effective adjuvant therapy.
  • International consensus conferences have attempted to standardize diagnostic and treatment approaches in the management of adrenal tumors; further research is necessary.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / drug therapy
  • [MeSH-minor] Adrenal Glands / pathology. Adrenal Glands / radiography. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / drug therapy. Adrenocortical Carcinoma / genetics. Chemotherapy, Adjuvant. Humans. Pheochromocytoma / diagnosis. Pheochromocytoma / drug therapy. Prognosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043254.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


13. Iihara M, Obara T: [Diagnosis and treatment for adrenocortical carcinoma]. Gan To Kagaku Ryoho; 2004 Mar;31(3):342-5
Hazardous Substances Data Bank. CHOLESTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment for adrenocortical carcinoma].
  • Adrenocortical carcinomas frequently hypersecrete multiple adrenocortical steroids and their precursors.
  • Therapy in patients with adrenocortical carcinoma is less satisfactory.
  • Surgical excision is the primary mode of therapy.
  • Up to the present, mitotane (o, p'-DDD) treatment combined with chemotherapy has been the only palliative measure for patients with nonresectable or extensively recurrent tumors.
  • [MeSH-major] Adrenal Cortex Neoplasms. Adrenocortical Carcinoma
  • [MeSH-minor] Adrenal Cortex / radionuclide imaging. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cholesterol. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Iodine Radioisotopes. Magnetic Resonance Imaging. Mitotane / administration & dosage. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15045937.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Iodine Radioisotopes; 6PLQ3CP4P3 / Etoposide; 78E4J5IB5J / Mitotane; 80168379AG / Doxorubicin; 97C5T2UQ7J / Cholesterol; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 12
  •  go-up   go-down


14. Nguyen T, Deangelis LM: Treatment of brain metastases. J Support Oncol; 2004 Sep-Oct;2(5):405-10; discussion 411-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of brain metastases.
  • Brain metastases are a common complication of cancer, found in approximately 20% of patients at autopsy.
  • Supportive therapies, such as corticosteroids, anticonvulsants, and anticoagulants, are necessary for most patients to address the common medical complications that often accompany brain metastases.
  • These treatments often ameliorate symptoms and signs and improve neurologic function, but they require careful management to minimize their common toxicities.
  • Definitive antitumor treatment may include whole-brain radiotherapy, surgery, stereotactic radiosurgery, and chemotherapy.
  • A multimodal approach can yield prolonged survival of a year or more in some patients, particularly those with limited intracranial disease, high performance status, limited systemic cancer burden, young age, and certain tumor pathologies.
  • However, even patients with poor prognostic factors can have some relief of neurologic symptoms and signs with the institution of therapy.
  • Patients with recurrent brain metastases can also benefit from additional treatment, including all the modalities available at diagnosis.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Anticoagulants / therapeutic use. Anticonvulsants / therapeutic use. Cranial Irradiation. Humans. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15524068.001).
  • [ISSN] 1544-6794
  • [Journal-full-title] The journal of supportive oncology
  • [ISO-abbreviation] J Support Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anticoagulants; 0 / Anticonvulsants
  • [Number-of-references] 31
  •  go-up   go-down


15. Wen PY, Loeffler JS: Brain metastases. Curr Treat Options Oncol; 2000 Dec;1(5):447-58
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain metastases are an increasingly common complication in patients with systemic cancer.
  • The optimal treatment for each patient depends on careful evaluation of several factors: the location, size, and number of brain metastases; the patient's age, general condition, and neurologic status; and the extent of systemic cancer to name a few.
  • For patients with a single brain metastasis and limited systemic disease, the standard treatment is surgical resection followed by whole brain radiation therapy.
  • Radiosurgery is effective in treating patients with a limited number of recurrent brain metastases and stable systemic diseases.
  • Surgery may have a role in patients with a large symptomatic recurrent lesion producing mass effect.
  • Reirradiation and chemotherapy may have a limited role in patients with multiple recurrent metastases.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / therapy. Neoplasms / therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Anticonvulsants / therapeutic use. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cranial Irradiation. Humans. Prognosis. Radiosurgery. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 1989 Nov;87(5):505-10 [2683764.001]
  • [Cites] Oncology (Williston Park). 1995 Nov;9(11):1205-12; discussion 1212-6, 1219 [8703690.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1093-112 [7677836.001]
  • [Cites] Arch Neurol. 1988 Jul;45(7):741-4 [3390029.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1625-9 [3171628.001]
  • [Cites] Semin Surg Oncol. 1998 Jan-Feb;14(1):70-8 [9407633.001]
  • [Cites] Surg Neurol. 1981 Jul;16(1):23-4 [7280966.001]
  • [Cites] Semin Surg Oncol. 1998 Jan-Feb;14(1):64-9 [9407632.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):549-58 [10078636.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):337-44 [8823767.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):765-73 [8625178.001]
  • [Cites] N Engl J Med. 1969 Jul 3;281(1):32-4 [5814988.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] Epilepsia. 1999 Mar;40(3):341-4 [10080516.001]
  • [Cites] Cancer. 1986 Aug 15;58(4):832-9 [3755076.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):711-7 [8040016.001]
  • [Cites] Curr Probl Cancer. 1999 Mar-Apr;23(2):59-98 [10333375.001]
  • [Cites] J Pediatr. 1983 Oct;103(4):558-61 [6620015.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):435-46 [8823773.001]
  • [Cites] Neurosurgery. 1997 Mar;40(3):518-23; discussion 523-5 [9055291.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):385-91 [9069311.001]
  • [Cites] Neurology. 2000 May 23;54(10):1886-93 [10822423.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2C):1611-7 [10365156.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1498-502 [1325541.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):393-423 [8823771.001]
  • [Cites] Neurology. 1994 Apr;44(4):675-80 [8164824.001]
  • [Cites] Cancer Metastasis Rev. 1991 Dec;10(4):335-41 [1786634.001]
  • [Cites] Nat Med. 1997 Dec;3(12):1354-61 [9396605.001]
  • [Cites] Oncology (Williston Park). 1999 Jul;13(7):941-54, 957-61; discussion 961-2, 9 [10442342.001]
  • [Cites] Am J Med. 1993 Feb;94(2):216-9 [8381584.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1998 May;78(1):91-3 [9605456.001]
  • [Cites] Neurology. 1996 Apr;46(4):985-91 [8780077.001]
  • [Cites] Am J Clin Oncol. 1990 Dec;13(6):507-9 [2173393.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1063-70 [9060546.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Apr 1;35(1):27-35 [8641923.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):445-54 [9308949.001]
  • [Cites] Radiology. 1990 Mar;174(3 Pt 1):883-5 [2305074.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):585-90 [8621282.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Jan;6(1):1-9 [6154024.001]
  • [Cites] J Clin Oncol. 1989 Jul;7(7):900-3 [2472471.001]
  • [Cites] J Am Med Assoc. 1957 Apr 20;163(16):1473-6 [13415910.001]
  • [Cites] Radiology. 1999 Sep;212(3):755-9 [10478243.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):600-4 [7674007.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):581-9 [9806518.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3563-9 [9817276.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 4;87(1):34-40 [7666461.001]
  • [Cites] J Neurooncol. 1991 Apr;10(2):173-7 [1716670.001]
  • [Cites] Semin Surg Oncol. 1998 Jan-Feb;14(1):53-63 [9407631.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):403-10 [9010115.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):433-7 [2841266.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1187-92 [9849477.001]
  • [Cites] Int J Oncol. 1998 Oct;13(4):801-5 [9735411.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Mar 1;28(4):797-802 [8138431.001]
  • [Cites] Neurology. 1989 Jun;39(6):789-96 [2725874.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1599-605 [10193952.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):35-43 [10389878.001]
  • [Cites] J Lancet. 1961 Feb;81:46-53 [13703072.001]
  • [Cites] Ann Neurol. 1992 Mar;31(3):268-73 [1637135.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1621-4 [3171627.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1485-9 [9809728.001]
  • [Cites] J Neurosurg. 1993 Aug;79(2):210-6 [8331402.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2593-603 [10561327.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):427-34 [10487566.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1470-6 [8839553.001]
  • [Cites] Oncology. 1996 May-Jun;53(3):210-3 [8643223.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):527-36 [8823780.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):485-95 [8823776.001]
  • [Cites] Ann Neurol. 1993 Jun;33(6):583-90 [8498838.001]
  • [Cites] Oncology (Williston Park). 1999 Oct;13(10):1397-409; discussion, 1409-10, 1413 [10549566.001]
  • [Cites] Can J Neurol Sci. 1995 Feb;22(1):13-6 [7750066.001]
  • [Cites] J Neurooncol. 1997 Jul;33(3):213-21 [9195493.001]
  • [Cites] N Engl J Med. 1990 Feb 22;322(8):494-500 [2405271.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):89-93 [9989518.001]
  • (PMID = 12057152.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anticonvulsants; 0 / Antineoplastic Agents
  • [Number-of-references] 82
  •  go-up   go-down


16. Bednarek-Tupikowska G, Florczak A, Witkiewicz W, Tupikowski W, Cisarz E: [A long term survival of the patient treated due to advanced adrenocortical carcinoma]. Pol Arch Med Wewn; 2005 May;113(5):462-5
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long term survival of the patient treated due to advanced adrenocortical carcinoma].
  • The authors presented a case of 52-years old woman with advanced adrenocortical carcinoma completely recovered after surgical resection followed by chemotherapy and mitotane treatment.
  • The authors accentuate a big value of postoperative control, especially imaging studies for early diagnosis of recurrent of cancer and beginning therapy.
  • [MeSH-major] Adrenal Cortex Neoplasms / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Disease-Free Survival. Female. Humans. Middle Aged. Mitotane / therapeutic use

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16479829.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


17. Schmuth M, Topar G, Illersperger B, Kowald E, Fritsch PO, Sepp NT: Therapeutic use of interferon-alpha for lymphomatoid papulosis. Cancer; 2000 Oct 1;89(7):1603-10
Genetic Alliance. consumer health - Lymphomatoid papulosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic use of interferon-alpha for lymphomatoid papulosis.
  • Therapeutic strategies for patients with lymphomatoid papulosis have been designed to prevent transformation but have proved to be either inefficacious or limited by side effects.
  • METHODS: The authors compared the clinical, histologic, and immunohistochemical features from a group of five patients receiving interferon-alpha (IFN-alpha) subcutaneously three times per week with the same features from a group of six patients receiving conventional therapy, including photochemotherapy, antibiotics, topical corticosteroids, or surgery, in an open trial.
  • RESULTS: In the IFN-alpha group, four patients showed a complete remission, and one patient showed a partial remission within a time period of 6 weeks.
  • Two patients developed disease recurrences after discontinuation of short term IFN-alpha therapy (5-7 months).
  • Thereof, one patient went into stable remission after long term IFN-alpha therapy (17 months), and one patient remains in partial remission.
  • In the control group, one patient went into spontaneous remission, two patients showed partial remission, of which one patient developed progressive disease at a later time point, whereas three patients have recurrent disease despite of treatment.
  • CONCLUSIONS: The current results indicate that the treatment with IFN-alpha of patients with lymphomatoid papulosis alters the clinical course of the disease with fewer side effects than previous regimens; however, short term treatment does not induce stable remission.
  • Therefore, prolonged treatment appears to be warranted for these patients.
  • [MeSH-major] Interferon-alpha / therapeutic use. Lymphomatoid Papulosis / drug therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Anti-Bacterial Agents / therapeutic use. Disease Progression. Female. Humans. Immunohistochemistry. Injections, Subcutaneous. Male. Middle Aged. Phototherapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11013377.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Bacterial Agents; 0 / Interferon-alpha
  •  go-up   go-down


18. Szilagyi A, Ghali MP: Pharmacological therapy of vascular malformations of the gastrointestinal tract. Can J Gastroenterol; 2006 Mar;20(3):171-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacological therapy of vascular malformations of the gastrointestinal tract.
  • While endoscopic coagulative therapy is the method of choice for controlling bleeding, a substantial number of cases require additional therapy.
  • Adjunctive or even primary phamacotherapy may be indicated in recurrent bleeding.
  • The present review compares the outcome of AVM after no intervention, coagulative therapy or focus on pharmacological agents.
  • Similarly, the bulk of information evaluates two therapies, hormones (estrogen and progesterone) and the somatostatin analogue octreotide.
  • Of these, the former is the only therapy evaluated in randomized trials, and the results are conflicting without clear guidelines.
  • The latter therapy has been reported only as case reports and case series without prospective trials.
  • In addition, other anecdotally used medications are discussed.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Arteriovenous Malformations / drug therapy. Gastrointestinal Diseases / drug therapy. Hemostatics / therapeutic use
  • [MeSH-minor] Female. Humans. Male. Prognosis. Risk Assessment. Severity of Illness Index. Survival Analysis. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Vascular Malformations.
  • MedlinePlus Health Information. consumer health - Arteriovenous Malformations.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Res. 1993 Oct;55(4):446-50 [7692142.001]
  • [Cites] Gut. 1994 Apr;35(4):461-3 [8174981.001]
  • [Cites] N Engl J Med. 1994 Jun 23;330(25):1789-90 [8190155.001]
  • [Cites] Am J Gastroenterol. 1995 Jan;90(1):154-6 [7801925.001]
  • [Cites] Am J Gastroenterol. 1995 Apr;90(4):564-7 [7717311.001]
  • [Cites] Endoscopy. 1995 Feb;27(2):164-70 [7601049.001]
  • [Cites] Dis Colon Rectum. 1995 Sep;38(9):979-82 [7656748.001]
  • [Cites] Gut. 1995 Aug;37(2):187-90 [7557565.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):246-54 [8532003.001]
  • [Cites] Nephrol Dial Transplant. 1996 May;11(5):871-4 [8671914.001]
  • [Cites] Thromb Haemost. 1995 Dec;74(6):1610-2 [8772248.001]
  • [Cites] Gastroenterologist. 1996 Sep;4(3):203-10 [8891684.001]
  • [Cites] Scand J Gastroenterol. 1996 Oct;31(10):1037-9 [8898427.001]
  • [Cites] Gastrointest Endosc Clin N Am. 1996 Oct;6(4):819-32 [8899412.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):425-8 [9068462.001]
  • [Cites] Am J Kidney Dis. 1998 Mar;31(3):536-8 [9506694.001]
  • [Cites] J Clin Gastroenterol. 1998 Jun;26(4):345-6 [9649027.001]
  • [Cites] J Pediatr Surg. 1998 Jul;33(7):1163-7 [9694115.001]
  • [Cites] Am J Gastroenterol. 1998 Aug;93(8):1250-4 [9707046.001]
  • [Cites] Am J Gastroenterol. 1999 Oct;94(10):2909-11 [10520843.001]
  • [Cites] J Am Med Assoc. 1952 Aug 9;149(15):1376-80 [14938187.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Jul 15;18(2):157-65 [12869075.001]
  • [Cites] N Engl J Med. 2003 Jul 24;349(4):343-9 [12878741.001]
  • [Cites] Scand J Gastroenterol. 2003 Jul;38(7):801-3 [12889571.001]
  • [Cites] Acta Haematol. 2003;110(1):29-32 [12975554.001]
  • [Cites] Transfus Med Rev. 2003 Oct;17(4):272-86 [14571395.001]
  • [Cites] Scand J Gastroenterol Suppl. 1998;228:115-21 [9867121.001]
  • [Cites] Am J Hematol. 1999 Feb;60(2):151-7 [9929110.001]
  • [Cites] Dig Dis Sci. 2004 May;49(5):885-7 [15259515.001]
  • [Cites] Arch Dermatol. 1973 Apr;107(4):571-3 [4697687.001]
  • [Cites] Am J Surg. 1975 Feb;129(2):212-6 [1078946.001]
  • [Cites] Gastroenterology. 1977 Apr;72(4 Pt 1):650-60 [300063.001]
  • [Cites] South Med J. 1979 Nov;72(11):1503 [315616.001]
  • [Cites] Dig Dis Sci. 1980 Mar;25(3):236-9 [6966212.001]
  • [Cites] Acta Med Scand. 1981;209(5):393-6 [7018182.001]
  • [Cites] Laryngoscope. 1982 Mar;92(3):314-20 [7040867.001]
  • [Cites] Lancet. 1982 Jul 3;2(8288):16-9 [6123752.001]
  • [Cites] Gastroenterology. 1984 Nov;87(5):1165-70 [6332757.001]
  • [Cites] Gut. 1985 Jun;26(6):586-93 [3874122.001]
  • [Cites] Gut. 1985 Dec;26(12):1338-48 [3878817.001]
  • [Cites] Ann Intern Med. 1986 Mar;104(3):352-4 [3484926.001]
  • [Cites] Dig Dis Sci. 1986 Sep;31(9 Suppl):26S-42S [3488186.001]
  • [Cites] Ann Intern Med. 1986 Sep;105(3):371-4 [3488703.001]
  • [Cites] Am Surg. 1988 Jan;54(1):56-9 [3257369.001]
  • [Cites] Am J Gastroenterol. 1988 May;83(5):556-8 [3259072.001]
  • [Cites] Ann Intern Med. 1988 Jul 15;109(2):171 [3382114.001]
  • [Cites] Mayo Clin Proc. 1988 Oct;63(10):993-1003 [3262793.001]
  • [Cites] J Clin Gastroenterol. 1988 Dec;10(6):676-9 [3265945.001]
  • [Cites] Dis Colon Rectum. 1989 Apr;32(4):296-8 [2784375.001]
  • [Cites] Int J Colorectal Dis. 1989;4(1):20-5 [2627207.001]
  • [Cites] Dig Dis Sci. 1989 Oct;34(10):1542-6 [2507262.001]
  • [Cites] Lancet. 1990 Apr 21;335(8695):953-5 [1970032.001]
  • [Cites] Dig Dis Sci. 1990 Jul;35(7):821-6 [2364836.001]
  • [Cites] Arch Intern Med. 1990 Aug;150(8):1744-6 [2116786.001]
  • [Cites] Isr J Med Sci. 1990 Sep;26(9):504-9 [2121664.001]
  • [Cites] Am J Surg. 1991 Feb;161(2):284-93 [1990883.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):1070-6 [10201485.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):1077-82 [10201486.001]
  • [Cites] Semin Gastrointest Dis. 1999 Apr;10(2):71-7 [10361898.001]
  • [Cites] Thromb Res. 1999 Oct 1;96(1):73-6 [10554087.001]
  • [Cites] Digestion. 1999;60 Suppl 3:1-16 [10567784.001]
  • [Cites] Aliment Pharmacol Ther. 1999 Nov;13(11):1429-36 [10571598.001]
  • [Cites] Gastroenterology. 2000 Jan;118(1):201-21 [10611170.001]
  • [Cites] Br J Haematol. 2000 Mar;108(3):524-7 [10759709.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2000 Apr;30(4):442-6 [10776959.001]
  • [Cites] Am J Surg. 2000 Sep;180(3):181-4 [11084125.001]
  • [Cites] Blood Coagul Fibrinolysis. 2001 Apr;12(3):211-3 [11414636.001]
  • [Cites] Dig Liver Dis. 2001 May;33(4):330-4 [11432511.001]
  • [Cites] Ann Rheum Dis. 2001 Aug;60(8):796-8 [11454645.001]
  • [Cites] N Engl J Med. 2001 Sep 20;345(12):926 [11565536.001]
  • [Cites] Haemophilia. 2001 Sep;7(5):500-3 [11554939.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2001 Aug;33(2):183-8 [11568521.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1073-9 [11677198.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Dig Dis Sci. 2002 Jul;47(7):1514-5 [12141810.001]
  • [Cites] Haematologica. 2002 Aug;87(8):ELT34 [12161379.001]
  • [Cites] J Intern Med. 2002 Sep;252(3):271-5 [12270009.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):2156; author reply 2156-7 [12454879.001]
  • [Cites] Am J Gastroenterol. 2003 Jan;98(1):59-65 [12526937.001]
  • [Cites] Am J Gastroenterol. 2003 Jan;98(1):221-2 [12526972.001]
  • [Cites] Dig Dis Sci. 2003 Oct;48(10):1919 [14627333.001]
  • [Cites] Gastroenterology. 2004 Mar;126(3):643-53 [14988816.001]
  • [Cites] N Engl J Med. 2004 Mar 4;350(10):1013-22 [14999113.001]
  • [Cites] Gut. 2004 Apr;53(4):609-12 [15016759.001]
  • [Cites] Am J Surg. 1992 Jan;163(1):90-2; discussion 92-3 [1733379.001]
  • [Cites] Surg Clin North Am. 1992 Jun;72(3):559-70 [1589831.001]
  • [Cites] Gut. 1992 May;33(5):715-7 [1612493.001]
  • [Cites] J Clin Gastroenterol. 1992 Sep;15(2):99-103 [1328358.001]
  • [Cites] Dis Colon Rectum. 1993 Feb;36(2):194-6 [8425426.001]
  • [Cites] Gut. 1993 Apr;34(4):470-5 [8491392.001]
  • [Cites] Am J Gastroenterol. 1993 Jun;88(6):807-18 [8389094.001]
  • [Cites] Am J Gastroenterol. 1993 Sep;88(9):1424-7 [8362842.001]
  • (PMID = 16550261.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Hemostatics
  • [Number-of-references] 98
  • [Other-IDs] NLM/ PMC2582970
  •  go-up   go-down


19. Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J, Gijtenbeek A, Schlegel U, Bergstrom P, Green S, Weir A, Nikolova Z: Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer; 2009 Dec 15;101(12):1995-2004
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs).
  • CONCLUSIONS: Imatinib in addition to hydroxyurea was well tolerated among patients with recurrent GBM but did not show clinically meaningful anti-tumour activity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy
  • [MeSH-minor] Adolescent. Adrenal Cortex Hormones / administration & dosage. Adult. Aged. Benzamides. Biomarkers, Tumor / analysis. Female. Humans. Hydroxyurea / administration & dosage. Hydroxyurea / adverse effects. Hydroxyurea / pharmacokinetics. Imatinib Mesylate. Male. Middle Aged. Piperazines / administration & dosage. Piperazines / adverse effects. Piperazines / pharmacokinetics. Proto-Oncogene Proteins c-kit / genetics. Pyrimidines / administration & dosage. Pyrimidines / adverse effects. Pyrimidines / pharmacokinetics. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] Lancet Oncol. 2008 May;9(5):453-61 [18452856.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3791-6 [18669467.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4659-65 [18824712.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5143-50 [11016641.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2929-34 [11306470.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3729-35 [12097282.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5476-84 [12359756.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Mar;304(3):1085-92 [12604685.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):458-70 [12644539.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):39-44 [12798163.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3779-87 [14506171.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 10;310(1):135-42 [14511660.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7377-83 [14612536.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6534-44 [14695158.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):897-908 [14871965.001]
  • [Cites] Leukemia. 2004 Mar;18(3):409-14 [14712290.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2333-7 [15059881.001]
  • [Cites] Mol Pharmacol. 2004 Jun;65(6):1485-95 [15155841.001]
  • [Cites] Cytokine Growth Factor Rev. 2004 Aug;15(4):275-86 [15207817.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):3910-8 [2454731.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Oncol. 1992 May;10(5):766-71 [1314890.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1607-15 [8040673.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Neurosurgery. 1996 Nov;39(5):921-6 [8905746.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1063-70 [9060546.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):57-63 [9422558.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11410-5 [10500190.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4514-22 [15542802.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):939-52 [15557593.001]
  • [Cites] Blood Cells Mol Dis. 2005 Mar-Apr;34(2):181-5 [15727903.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Pathol. 2005 Oct;207(2):224-31 [16021678.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1702-8 [16033874.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9359-68 [16361636.001]
  • [Cites] Oncogene. 2006 Aug 10;25(35):4913-22 [16547494.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Neuro Oncol. 2007 Jan;9(1):29-38 [17108063.001]
  • [Cites] J Neurooncol. 2007 May;83(1):53-60 [17245623.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Neuro Oncol. 2008 Jun;10(3):361-7 [18401015.001]
  • (PMID = 19904263.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; X6Q56QN5QC / Hydroxyurea
  • [Other-IDs] NLM/ PMC2795431
  •  go-up   go-down


20. Amada N, Kikuchi H, Haga I, Fukumori T, Sato A, Sato T: Successful steroid withdrawal after long-term administration in renal transplant patients. Transplant Proc; 2009 Jan-Feb;41(1):135-7
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Twelve patients out of 47 had to resume steroid administration, 10 (21%) owing to acute rejection with/without recurrent glomerulonephritis, 1 owing to treatment of subacute thyroiditis, and the other owing to accompanying cessation of azathioprine for ovarian cancer.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Kidney Transplantation / physiology
  • [MeSH-minor] Cadaver. Drug Administration Schedule. Female. Follow-Up Studies. Graft Rejection / drug therapy. Humans. Living Donors. Male. Nuclear Family. Outpatients. Ovarian Neoplasms / epidemiology. Postoperative Complications / epidemiology. Prednisolone / administration & dosage. Prednisolone / therapeutic use. Renal Dialysis. Retrospective Studies. Safety. Time Factors. Tissue Donors

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249498.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


21. Tasaka S, Tomomatsu K, Funatsu Y, Soejima K, Ishizaka A: Acute respiratory distress syndrome after percutaneous cryotherapy for a pulmonary metastatic lesion. Intern Med; 2010;49(5):431-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Percutaneous cryotherapy (PCT) under computed tomographic guidance is minimally invasive, with satisfactory local control of primary lung cancer and pulmonary metastatic lesions.
  • We report a case of acute respiratory distress syndrome (ARDS) in a patient who underwent PCT for lung metastasis of recurrent esophageal cancer.
  • The patient responded to pulse steroid therapy and recovered from severe respiratory failure.
  • [MeSH-major] Cryotherapy / adverse effects. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Respiratory Distress Syndrome, Adult / diagnosis. Respiratory Distress Syndrome, Adult / etiology
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Dose-Response Relationship, Drug. Esophageal Neoplasms / pathology. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Respiratory Distress Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20190478.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


22. Zancanella P, Pianovski MA, Oliveira BH, Ferman S, Piovezan GC, Lichtvan LL, Voss SZ, Stinghen ST, Callefe LG, Parise GA, Santana MH, Figueiredo BC: Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression. J Pediatr Hematol Oncol; 2006 Aug;28(8):513-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
  • PURPOSE: To define a mitotane dose for pediatric patients with adrenocortical cancer (ACC) that maintains therapeutic plasma levels (TL) between 14 and 20 microg/mL and to verify its antitumor efficacy in association with 8 cycles of cisplatin, etoposide, and doxorubicin (CED).
  • Of the 3 patients who are alive at the time of report, 1 patient has been without disease for 16 months, and 2 patients have progressive disease.
  • All patients had recurrent metastatic disease (2 to 9 times).
  • CONCLUSIONS: Mitotane daily dose to maintain TL is variable and monitoring should start 1.5 months after the beginning of treatment.
  • CED combined with mitotane is the best available pharmacologic treatment for ACC, but further studies are required to characterize different profiles of therapeutic response.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Mitotane / administration & dosage
  • [MeSH-minor] Administration, Oral. Child. Child, Preschool. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Monitoring / methods. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Prospective Studies. Remission Induction. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912591.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 78E4J5IB5J / Mitotane; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Kakihana K, Ohashi K, Iguchi M, Negishi K, Suzuki T, Shitara M, Honma M, Akiyama H, Sakamaki H: Frequent exacerbation of pulmonary nocardiosis during maintenance antibiotic therapies in a hematopoietic stem cell transplant recipient. Int J Hematol; 2007 Dec;86(5):455-8
MedlinePlus Health Information. consumer health - Antibiotics.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent exacerbation of pulmonary nocardiosis during maintenance antibiotic therapies in a hematopoietic stem cell transplant recipient.
  • We describe a rare case of recurrent pulmonary nocardiosis (PN) in a hematopoietic stem cell transplant recipient.
  • The patient developed Nocardia farcinica infection while receiving corticosteroid and cyclosporine for the treatment of bronchiolitis obliterans, probably due to chronic graft-versus-host disease (cGVHD).
  • The patient responded well to the initial treatment with meropenem, but PN recurred 3 times during oral maintenance therapies using different antibiotics, which were chosen on the basis of the results of in vitro susceptibility testing against N farcinica Minocycline, amoxicillin/clavulanate, and levofloxacin were not effective as oral maintenance therapies.
  • [MeSH-major] Anti-Bacterial Agents / administration & dosage. Hematopoietic Stem Cell Transplantation. Nocardia. Nocardia Infections / drug therapy. Pneumonia, Bacterial / drug therapy
  • [MeSH-minor] Adolescent. Adrenal Cortex Hormones / administration & dosage. Adrenal Cortex Hormones / adverse effects. Bronchiolitis Obliterans / complications. Bronchiolitis Obliterans / diagnostic imaging. Bronchiolitis Obliterans / drug therapy. Chronic Disease. Graft vs Host Disease / complications. Graft vs Host Disease / diagnostic imaging. Graft vs Host Disease / drug therapy. Humans. Male. Tomography, X-Ray Computed. Transplantation, Homologous

  • Genetic Alliance. consumer health - Nocardiosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1994;14 Suppl 4:S19-28 [7728120.001]
  • [Cites] Respiration. 2001;68(4):382-8 [11464085.001]
  • [Cites] Arch Intern Med. 1983 Apr;143(4):711-8 [6340623.001]
  • [Cites] Medicine (Baltimore). 2002 Sep;81(5):388-97 [12352633.001]
  • [Cites] Chest. 1993 Mar;103(3):951-2 [8449101.001]
  • [Cites] Clin Infect Dis. 1996 Nov;23(5):1012-9 [8922795.001]
  • [Cites] Br J Haematol. 2004 Sep;126(6):758 [15352978.001]
  • [Cites] Transpl Int. 2005 Sep;18(9):1048-53 [16101725.001]
  • [Cites] Clin Microbiol Rev. 2006 Apr;19(2):259-82 [16614249.001]
  • [Cites] South Med J. 1993 Feb;86(2):225-8 [8434299.001]
  • [Cites] Bone Marrow Transplant. 1995 Mar;15(3):479-81 [7599576.001]
  • [Cites] Clin Infect Dis. 1997 Jun;24(6):1154-60 [9195074.001]
  • [Cites] Chest. 1996 Apr;109(4):1066-77 [8635332.001]
  • [Cites] Semin Respir Infect. 1990 Mar;5(1):74-9 [2188320.001]
  • (PMID = 18192116.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Bacterial Agents
  •  go-up   go-down


24. Safdar A, Rodriguez GH, Lichtiger B, Dickey BF, Kontoyiannis DP, Freireich EJ, Shpall EJ, Raad II, Kantarjian HM, Champlin RE: Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer; 2006 Jun 15;106(12):2664-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The response to antifungal therapy alone often is suboptimal in patients with cancer who have therapy-refractory neutropenia, and even donor-derived granulocyte transfusions (GTX) are not always successful.
  • The authors evaluated the safety and efficacy of immune enhancement using recombinant interferon gamma1b (rIFN-gamma1b) in patients with cancer who received GTX for refractory, systemic, opportunistic infections.
  • Most patients (n = 18 patients; 90%) had recurrent or refractory cancer.
  • Seventeen patients (85%) had neutropenia during GTX therapy.
  • Eight patients (40%) received corticosteroids during GTX plus rIFN-gamma1b therapy.
  • Four patients (20%) developed fever, and 2 patients (10%) developed skin rashes.
  • Four weeks after therapy started, 9 patients (45%) had complete or partial resolution of infection; and, in another 3 patients (15%), the invasive fungal infection had become stable.
  • CONCLUSIONS: The current results indicated that no serious adverse events were associated with rIFN-gamma1b immune enhancement in patients with systemic opportunistic infections who received donor GTX therapy.
  • [MeSH-major] Antifungal Agents / immunology. Antifungal Agents / therapeutic use. Granulocytes / transplantation. Hematologic Neoplasms / complications. Interferon-gamma / immunology. Interferon-gamma / therapeutic use. Leukocyte Transfusion. Mycoses / drug therapy. Opportunistic Infections / drug therapy. Recombinant Proteins / therapeutic use
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Child. Combined Modality Therapy. Cytokines / therapeutic use. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Drug Therapy, Combination. Female. Gram-Negative Bacterial Infections / complications. Gram-Negative Bacterial Infections / drug therapy. Gram-Negative Bacterial Infections / mortality. Humans. Male. Middle Aged. Neutropenia / etiology. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16691620.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antifungal Agents; 0 / Cytokines; 0 / Recombinant Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down






Advertisement